https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-08 / Mol. Ther. 2010 Feb;18(2):264-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-08 / Mol. Ther. 2010 Feb;18(2):264-742009-09-08 00:00:002019-02-15 08:44:16Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:41-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:41-502009-09-01 00:00:002019-02-15 08:44:15Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:18-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:18-232009-09-01 00:00:002019-02-15 08:59:38Brain tumor immunotherapy with type-1 polarizing strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-812009-09-01 00:00:002019-02-15 08:48:08Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Prostate 2009 Sep;69(12):1343-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Prostate 2009 Sep;69(12):1343-522009-09-01 00:00:002019-02-15 08:48:19Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-222009-09-01 00:00:002021-11-15 17:00:58Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:88-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:88-982009-09-01 00:00:002019-02-15 08:44:14Harnessing dendritic cells to generate cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-08-08 / Med. Oncol. 2010 Sep;27(3):736-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-08-08 / Med. Oncol. 2010 Sep;27(3):736-422009-08-08 00:00:002019-02-15 08:46:07Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-08-01 / Stem Cells 2009 Aug;27(8):1734-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-08-01 / Stem Cells 2009 Aug;27(8):1734-402009-08-01 00:00:002019-02-15 08:46:46Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-08-01 / Expert Rev Anticancer Ther 2009 Aug;9(8):1065-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-08-01 / Expert Rev Anticancer Ther 2009 Aug;9(8):1065-712009-08-01 00:00:002019-02-15 08:53:17Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities
